Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

This is a retrospective analysis on the safety and activity of compassionate Ipilimumab and Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as a first-line regimen. IPI w...

Full description

Bibliographic Details
Main Authors: Antonuzzo, L. (Author), Atzori, F. (Author), Basso, U. (Author), Bracarda, S. (Author), Carella, C. (Author), Cartenì, G. (Author), Cusmai, A. (Author), D’arcangelo, M. (Author), De Giorgi, U. (Author), Deppieri, F.M (Author), Fornarini, G. (Author), Fratino, L. (Author), Panni, S. (Author), Paolieri, F. (Author), Pipitone, S. (Author), Procopio, G. (Author), Rizzo, M. (Author), Santoni, M. (Author), Tortora, G. (Author), Zagonel, V. (Author), Zucali, P. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
immune-related adverse events
ipilimumab
metastatic Renal Cell Carcinoma
nivolumab
progression
retrospective
survival
toxicity
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items